Skip to main content

Table 1 Baseline patient demographics and disease characteristics (intent-to-treat population)

From: Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection

 

Simeprevir 75 mg + TMC647055/ritonavir 450/30 mg

Simeprevir 75 mg + TMC647055/ritonavir 600/50 mg

Simeprevir 75 mg + TMC647055/ ritonavir 450/30 mg + JNJ-56914845 30 mg

Simeprevir 75 mg + TMC647055/ritonavir 450/30 mg + JNJ-56914845 60 mg

 

Panel 1

Panel 2

Panel 3

Panel 4

 

GT1a/with ribavirin (n = 10)

GT1b/with ribavirin (n = 12)

GT1b/without ribavirin (n = 9)

GT1a/with ribavirin (n = 7)

GT1b/without ribavirin (n = 8)

GT1a/b/other (n = 22)a

GT1a/b/other (n = 22)b

Caucasian, n (%)

10 (100)

12 (100)

8 (89)

7 (100)

6 (75)

20 (91)

21 (96)

Male, n (%)

8 (80)

4 (33)

7 (78)

7 (100)

3 (38)

16 (73)

17 (77)

Treatment-naïve, n (%)

10 (100)

8 (67)

8 (89)

7 (100)

4 (50)

20 (91)

19 (86)

Prior relapser, n (%)

0 (0)

4 (33)

1 (11)

0 (0)

4 (50)

2 (9)

3 (14)

Age, median, years (range)

46.5 (38–52)

47.5 (29–62)

37.0 (18–64)

44.0 (28–58)

48.5 (43–66)

50.5 (24–70)

48.0 (27–58)

HCV RNA, median, log10 IU/mL (range)

6.52 (4.4–7.2)

6.69 (5.8–7.5)

5.98 (5.3–7.1)

6.32 (6.0–7.4)

6.76 (6.1–7.0)

6.78 (5.5–7.4)

6.62 (5.2–7.1)

METAVIR score, n (%)

 F0–F2

5 (50)

6 (50)

6 (67)

4 (29)

3 (38)

7 (32)

5 (23)

 F3

1 (10)

1 (8)

1 (11)

1 (14)

0

2 (9)

4 (18)

 Missing

4 (40)

5 (42)

2 (22)

2 (29)

5 (63)

13 (59)

13 (59)

IL28B genotype, n (%)

 CC

5 (50)

4 (33)

2 (22)

0 (0)

2 (25)

9 (41)

6 (27)

 CT

4 (40)

6 (50)

6 (67)

6 (86)

5 (63)

8 (36)

11 (50)

 TT

1 (10)

2 (17)

1 (11)

1 (14)

1 (13)

5 (23)

5 (23)

  1. GT genotype, HCV hepatitis C virus
  2. aGT1a/other, n = 14; GT1b, n = 8. GT1a/other includes one patient with HCV GT1c and one patient with GT1l, as determined by NS5B sequencing
  3. bGT1a/other, n = 15; GT1b, n = 7